The ReTAVI Prospective Observational Registry

Condition(s) studied

Investigational drug(s) / intervention(s)

Elective redo transcatheter aortic valve implantation (redo-TAVI): Elective redo-TAVI procedure with the intention to treat the patient with a SAPIEN family valve implantation (currently the only registered medical devices for redo-TAVI use)

Study summary

Patients with severe aortic stenosis (sAS) treated with transcatheter aortic valve implantation (TAVI) (increasingly younger \& lower risk pts) are experiencing SVD of the index THV and thus developing an indication for a redo-TAVI procedure.

The evidence on redo-TAVI (where a transcatheter heart valve \[THV\] is implanted into another THV) is limited, with initial data showing acceptable safety as well efficacy in highly selected and limited populations.

Aim is to evaluate short- and long-term data on patients undergoing transcatheter redo-TAVI procedures with THVs for failure of a previously implanted THV and to determine VARC-3 defined efficacy and safety at 30 days and functional outcome at 1 year, 3 years and 5 years.

Eligibility

Primary outcome measure(s)

• Efficacy: VARC-3 defined device success at 30 days — 30 days
  Determine VARC-3 defined device success at 30 days * Technical success * Freedom from mortality * Freedom from surgery or intervention related to the device or a major vascular or access-related or cardiac structural complication * Intended performance of the valve (mean gradient \<20 mmHg, peak velocity \<3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation) (Different definitions, in addition to the predefined such as the consideration of higher gradients than 20 mmHg, will be explored) These events will be adjudicated. Number and percentage of subjects with device success at 30 days as per VARC-3 definition, along with individual component of the success, will be presented.
• Technical success: Technical success (at exit from procedure room) — end of intervention
  Technical success at exit from procedure room defined as: * Freedom from mortality * Successful access, delivery of the device, and retrieval of the delivery system * Correct positioning of a single prosthetic heart valve into the proper anatomical location * Freedom from surgery or intervention related to the device (excluding pacemaker) or to a major vascular or access-related, or cardiac structural complication Number and percentage of subjects with technical success at exit from procedure room, along with individual component of the success, will be presented.
• Safety: VARC-3 defined early safety at 30 days — 30 days
  Determine VARC-3 defined early safety at 30 days: * Freedom from all-cause mortality * Freedom from all Stroke * Freedom from all VARC type 2-4 bleeding * Freedom from all major vascular, access-related, or cardiac structural complication * Freedom from all acute kidney injury stage III/IV * Freedom from all moderate/severe aortic regurgitation * Freedom from all new permanent pacemaker implantations due to procedure-related conduction abnormalities * Freedom from all surgery/intervention related to the device These events will be adjudicated. Number and percentage of subjects with early safety at 30 days as per VARC-3 definition, along with individual component of the success, will be presented.
• Procedural Outcomes (30 days) — 30 days
  Procedural outcomes at 30 days, defined as: * Clinical and anatomical predictors of technical success (type of SVD \[stenosis vs. regurgitation\], valve size, implant depth, redo-TAVI balloon dilation, CT and echo-derived variables, etc.) * Rate of central and paravalvular regurgitation * Valve performance, including residual mean gradient * Risk and predictors of coronary obstruction Number and percentage of subjects with above specified outcomes at 30 days , along with individual component of the success, will be presented.
• Durability of the second aortic THV (30 days) — 30 days
  Determine the durability of the second aortic THV: * Subclinical transcatheter heart valve thrombosis at thirty days (when it becomes apparent, but no systematic screening) * Endocarditis Definition of transcatheter heart valve thrombosis Clinical sequelae of a thromboembolic event (e.g. stroke, TIA, retinal occlusion, other evidence of systemic thromboembolism) or worsening valve stenosis/ regurgitation (e.g. signs of heart failure, syncope) and * Haemodynamic valve deterioration Stage 2 or 3 or * Confirmatory imaging (CT evidence of HALT† or TEE findings) In the absence of clinical sequelae, both * Haemodynamic valve deterioration Stage 3 and * Confirmatory imaging (CT evidence of HALT or TEE findings) Number and percentage of subjects with above specified criteria at 3 months, along with individual component of the success, will be presented.
• Durability of the second aortic THV (3 months) — 3 months
  Determine the durability of the second aortic THV: * Subclinical transcatheter heart valve thrombosis at three months (if data obtained, when it becomes apparent, but no systematic screening) * Clinical transcatheter heart valve thrombosis at three months (if data obtained) * Endocarditis For the definition of transcatheter cardiac valve thrombosis, please refer to Outcome 5. Number and percentage of subjects with above specified criteria at 3 months, along with individual component of the success, will be presented.
• Durability of the second aortic THV (12 months) — 12 months
  Determine the durability of the second aortic THV: * Subclinical transcatheter heart valve thrombosis at twelve months (when it becomes apparent, but no systematic screening) * Clinical transcatheter heart valve thrombosis at twelve months * All-cause mortality, stroke, myocardial infarction, and cardiovascular hospitalization at twelve months * Stage II or III structural valve degeneration according to VARC 3 definitions at twelve months (stage I may be documented) * Endocarditis For the definition of transcatheter cardiac valve thrombosis, please refer to Outcome 5. Number and percentage of subjects with above specified criteria at 12 months , along with individual component of the success, will be presented.
• Durability of the second aortic THV (3 years) — 3 years
  Determine the durability of the second aortic THV: * Subclinical transcatheter heart valve thrombosis at 3 years (when it becomes apparent, but no systematic screening) * Clinical transcatheter heart valve thrombosis at 3 years * All-cause mortality, stroke, myocardial infarction, and cardiovascular hospitalization at 3 years For the definition of transcatheter cardiac valve thrombosis, please refer to Outcome 5.
• Durability of the second aortic THV (5 years) — 5 years
  Determine the durability of the second aortic THV: * Subclinical transcatheter heart valve thrombosis at 5 years (when it becomes apparent, but no systematic screening) * Clinical transcatheter heart valve thrombosis at 5 years * All-cause mortality, stroke, myocardial infarction, and cardiovascular hospitalization at 5 years For the definition of transcatheter cardiac valve thrombosis, please refer to Outcome 5.

Trial sites (62)

+ 22 more sites — see the full list on the official registry below.

More Institut für Pharmakologie und Präventive Medizin trials in Canada

Other trials for the same condition